Tanya Simuni, MD
Director, Parkinson's Disease and Movement Disorders Program at Northwestern University
Location: Chicago, Illinois, United States
Dr. Simuni graduated with her medical degree from Leningrad Medical School and completed an internship in medicine in Leningrad, Russia. She subsequently completed an internship in internal medicine at Albert Einstein Medical Center and a neurology residency and a clinical neurophysiology fellowship at Temple University in Philadelphia, Pennsylvania. She then pursued a movement disorders fellowship at the University of Pennsylvania, where she served on the clinical faculty of the Department of Neurology for three years and held the position of Medical Co-Director of the Parkinsonís disease (PD) and Movement Disorders surgical program prior to her current positions.
Dr. Simuni joined the faculty of the Northwestern University Feinberg School of Medicine in 2000 to build and lead a multidisciplinary movement disorders center that is recognized by the National Parkinsonís Foundation and Wilsonís Foundation† as a Center of Excellence and serves as a training model in the region. She is the lead investigator of a number of clinical trials on experimental pharmacology, non-motor manifestations, and pharmacological management of PD. Dr Simuni is currently the Investigator of more than a dozen PD clinical trials. She is the national principal investigator on a multicenter phase 3 clinical trial supported by a 16 million dollars grant from the National Institute of Health that is evaluating isradipine as a potential disease-modifying agent in early PD. She serves on a number of Steering Committees for the PD national clinical trials, several committees of the Parkinson Study Group and the National Parkinson Foundation. She is the Site PI and serve on the Steering Committee for the largest PD biomarker initiative funded by the MJFF (PPMI study). Dr. Simuni is the site PI for the Network for Excellence in Neuroscience Clinical Trials (NEXT) Northwestern Clinical Site (U10). She has more than hundred publications in peer-reviewed scientific journals and book chapters and she has lectured nationally and internationally on PD and other movement disorders.† In addition to her research career, Dr Simuni is highly committed to education of the next generation of physician s and has served as the Northwestern Neurology residency program director from 2001 to 2014.
Dr. Simuni is an active member of the American Academy of Neurology, American Neurological Association, and the Movement Disorders Society as well as the Parkinsonís Study Group, and REM Behavior Disorders Study Group.†
- Phase IIa Safety and Tolerability Trial of Nilotinib in People with Parkinson's Disease (2017)
- Planning Phase for a Phase IIa Study of Nilotinib in People with Parkinson's Disease (2016)
- High resolution diffusion tensor MRI imaging as a biomarker of Parkinson Disease diagnosis and disease progression (2009)
- Biomarkers of Pioglitazone Effects in Parkinson's Disease (BioPEP) (2009)
- Phase II Study of Isradipine as a Disease-modifying Agent in Early Parkinson's Disease (2008)